Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Exelixis Inc (NQ: EXEL ) 25.73 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Aug 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Exelixis Inc < Previous 1 2 3 4 5 6 7 8 9 Next > The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout June 29, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 28) Alexion Pharmaceuticals,... Via Benzinga Saint Warren June 28, 2021 Today the WTI oil price rose further up over 1%. Via Talk Markets 60 Biggest Movers From Yesterday June 29, 2021 Gainers Marin Software Incorporated (NASDAQ: MRIN) surged 96.9% to close at $7.50. Marin Software, last week, announced it has added the ability to manage Instacart Ads to its... Via Benzinga Mid-Afternoon Market Update: Nasdaq Gains 100 Points; New Senior Investment Shares Spike Higher June 28, 2021 Toward the end of trading Monday, the Dow traded down 0.49% to 34,266.49 while the NASDAQ rose 0.72% to 14,463.26. The S&P also rose, gaining 0.05% to 4,283.04. The U.S. has... Via Benzinga Topics Stocks Exposures US Equities Exelixis Stock Collapses; Can It Recover From Mixed Results In Liver Cancer Study? June 28, 2021 Exelixis reported mixed results for its advanced liver cancer treatment on Monday and EXEL stock collapsed to a seven-month low. Via Investor's Business Daily 12 Health Care Stocks Moving In Monday's Intraday Session June 28, 2021 Gainers Intellia Therapeutics (NASDAQ:NTLA Via Benzinga Mid-Day Market Update: Crude Oil Down Over 1%; Intellia Therapeutics Shares Jump June 28, 2021 Midway through trading Monday, the Dow traded down 0.52% to 34,253.86 while the NASDAQ rose 0.72% to 14,463.56. The S&P also fell, dropping 0.01% to 4,280.50. The U.S. has the... Via Benzinga Topics Stocks Exposures Fossil Fuels US Equities Here's Why Exelixis Stock Is Dropping Today June 28, 2021 The company reported successful clinical trial results, but investors were still disappointed. Via The Motley Fool 44 Stocks Moving In Monday's Mid-Day Session June 28, 2021 Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares climbed 43.5% to $127.44 after the company announced positive clinical data for its CRISPR therapy. Marin Software... Via Benzinga Exelixis Shares Drop On Mixed Results For Cabometyx Combo In Early Liver Cancer June 28, 2021 Exelixis Inc (NASDAQ: EXEL) and Ipsen (OTC: IPSEY) have announced mixed interim results from the COSMIC-312 Phase 3 trial evaluating cabozantinib (... Via Benzinga 12 Health Care Stocks Moving In Monday's Pre-Market Session June 28, 2021 Gainers Intellia Therapeutics (NASDAQ:NTLA) stock rose 62.0% to $143.91 during Monday's pre-market session. The company's market cap stands at $9.8 billion.... Via Benzinga The Week Ahead In Biotech: Mediwound, Provention FDA Decisions, IPOs, Pending Clinical Readouts In Focus June 27, 2021 Biotech stocks reversed course and closed the week ended June 25 higher, thanks to the positive broader market sentiment. Eli Lilly and Company (NYSE: LLY) stood out among big... Via Benzinga Exposures Product Safety Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2021 June 15, 2021 Upgrades According to Raymond James, the prior rating for Welltower Inc (NYSE:WELL) was changed from Market Perform to Strong Buy. For the first quarter, Welltower had an... Via Benzinga Unheeding Markets June 10, 2021 Today oil prices rose over $70. Via Talk Markets Here's What Crushed Exelixis' Earnings June 06, 2021 R&D spending is hurting earnings, but long-term investors shouldn't be worried. Via The Motley Fool 2 Top Biotech Stocks to Buy Right Now May 30, 2021 One is growing revenue. And the other may soon launch its first product. Via The Motley Fool Exposures COVID-19 3 Cheap Pharmaceutical Stocks to Grab Now May 28, 2021 The pharmaceutical industry has been the beneficiary of significant investor attention amid the COVID-19 pandemic as society turned to its products to fight the coronavirus. Via Talk Markets Exposures COVID-19 Sterling At Five-Year High May 25, 2021 Today markets are mixed because of currency factors, with sterling bullishness against the dollar and the euro. Via Talk Markets The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal May 25, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 24) Bristol-Myers Squibb Company... Via Benzinga Exelixis' Cabometyx, Roche's Tecentriq Combo Achieves 27% ORR in High-Risk Prostate Cancer Patients May 25, 2021 Exelixis Inc (NASDAQ: EXEL) has announced results from cohort 6 of the COSMIC-021 Phase 1b trial evaluating Cabometyx (cabozantinib) in combination... Via Benzinga 12 Health Care Stocks Moving In Monday's After-Market Session May 24, 2021 Gainers OptiNose (NASDAQ:OPTN) stock rose... Via Benzinga Is Exelixis a Buy? May 22, 2021 Revenue growth will probably accelerate soon, but it might not be enough. Via The Motley Fool What Investors Should Look for With Exelixis, DermTech, and Teladoc Health May 21, 2021 All three healthcare stocks could have solid growth prospects. Via The Motley Fool Why Is GlaxoSmithKline Selling Its Income Stream to Royalty Pharma? May 09, 2021 Apparently, up-front capital is better than royalties on drugs the pharma doesn't have control over. Via The Motley Fool Exelixis Inc (EXEL) Q1 2021 Earnings Call Transcript May 07, 2021 EXEL earnings call for the period ending March 31, 2021. Via The Motley Fool Topics Earnings Exposures Financial Exelixis: Q1 Earnings Insights May 06, 2021 Shares of Exelixis (NASDAQ:EXEL) increased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share decreased 52.63% over the past year... Via Benzinga The Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Split April 15, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 14) 10x Genomics, Inc. (NASDAQ... Via Benzinga Exposures COVID-19 < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.